HomeATAI • NASDAQ
ATAI Life Sciences NV
add
$1.48
19.35%
After Hours:(7.43%)-0.11
$1.37
Closed: Apr 2, 8:00:00 PM UTC-4 · USD · NASDAQ · Disclaimer
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | -5.00K | -127.78% |
Operating expense | 29.34M | -12.62% |
Net income | -38.96M | -112.98% |
Net profit margin | 779.16K | 866.72% |
Earnings per share | -0.24 | -100.00% |
EBITDA | -29.12M | 12.97% |
Effective tax rate | 1.81% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 62.33M | -65.23% |
Total assets | 159.39M | -45.69% |
Total liabilities | 42.83M | -12.87% |
Total equity | 116.55M | — |
Shares outstanding | 198.31M | — |
Price to book | 1.80 | — |
Return on assets | -41.11% | — |
Return on capital | -46.44% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -38.96M | -112.98% |
Cash from operations | -24.30M | -10.62% |
Cash from investing | 6.56M | 897.08% |
Cash from financing | 154.00K | 101.82% |
Net change in cash | -17.46M | 44.50% |
Free cash flow | -1.72M | 86.74% |
Previous close
$1.24
Day range
$1.27 - $1.48
Year range
$1.03 - $2.85
Market cap
293.49M USD
Avg Volume
2.19M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine.
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff.
Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
Founded
2018
Website
Employees
54
